Central Nervous System Drugs (Ch. 20-35+71) Flashcards
(149 cards)
A psychiatric nurse is teaching a patient about an antidepressant medication. The nurse tells the patient that therapeutic effects may not occur for several weeks. The nurse understands that this is likely the result of:
a.
changes in the brain as a result of prolonged drug exposure.
b.
direct actions of the drug on specific synaptic functions in the brain.
c.
slowed drug absorption across the blood-brain barrier.
d.
tolerance to exposure to the drug over time.
A
It is thought that beneficial responses to central nervous system (CNS) drugs are delayed because they result from adaptive changes as the CNS modifies itself in response to prolonged drug exposure, and that the responses are not the result of the direct effects of the drugs on synaptic functions. The blood-brain barrier prevents protein-bound and highly ionized drugs from crossing into the CNS, but it does not slow the effects of drugs that can cross the barrier. Tolerance is a decreased response to a drug after prolonged use.
A nurse is teaching a group of nursing students how the CNS adapts to psychotherapeutic medications. Which statement by a nursing student indicates a need for further teaching?
a.
“Adaptation can lead to tolerance of these drugs with prolonged use.”
b.
“Adaptation helps explain how physical dependence occurs.”
c.
“Adaptation often must occur before therapeutic effects develop.”
d.
“Adaptation results in an increased sensitivity to side effects over time.”
D
With adaptation of the central nervous system to prolonged exposure to CNS drugs, many adverse effects diminish and therapeutic effects remain. Adaptation helps explain how tolerance and physical dependence occur, as the brain adapts to the presence of the drug. Therapeutic effects can take several weeks to manifest, because they appear to work by initiating adaptive changes in the brain.
A group of nursing students asks a nurse to explain the blood-brain barrier. The nurse would be correct to say that the blood-brain barrier:
a.
prevents some potentially toxic substances from crossing into the central nervous system.
b.
causes infants to be less sensitive to CNS drugs and thus require larger doses.
c.
allows only ionized or protein-bound drugs to cross into the central nervous system.
d.
prevents lipid-soluble drugs from entering the central nervous system.
A
The blood-brain barrier can prevent some drugs and some toxic substances from entering the CNS. The blood-brain barrier in infants is not fully developed, so infants are more sensitive to CNS drugs and often require lower doses. The blood-brain barrier prevents highly ionized and protein-bound drugs from crossing into the CNS and allows lipid-soluble drugs and those that can cross via specific transport systems to enter.
A nurse is teaching a group of students about how CNS drugs are developed. Which statement by a student indicates a need for further teaching?
a.
“Central nervous system drug development relies on observations of their effects on human behavior.”
b.
“Studies of new central nervous system drugs in healthy subjects can produce paradoxical effects.”
c.
“Our knowledge of the neurochemical and physiologic changes that underlie mental illness is incomplete.”
d.
“These drugs are developed based on scientific knowledge of CNS transmitters and receptors.”
D
The deficiencies in knowledge about how CNS transmitters and receptors work make systematic development of CNS drugs difficult. Testing in healthy subjects often leads either to no effect or to paradoxical effects. Medical knowledge of the neurochemical and physiologic changes underlying mental illness is incomplete. The development of CNS drugs depends less on knowledge of how the CNS functions and how these drugs effect that process and more on how administering one of these agents leads to changes in behavior.
A patient asks a nurse to explain what drug tolerance means. The nurse responds by telling the patient that when tolerance occurs, it means the patient:
a.
has developed a psychologic dependence on the drug.
b.
may need increased amounts of the drug over time.
c.
will cause an abstinence syndrome if the drug is discontinued abruptly.
d.
will have increased sensitivity to drug side effects.
B
When tolerance develops, a dose increase may be needed, because a decreased response may occur with prolonged use. Psychologic dependence involves cravings for drug effects and does not define tolerance. Physical dependence occurs when the drug becomes necessary for the brain to function “normally,” meaning the patient should be weaned from the drug slowly to prevent an abstinence syndrome. Patients may have a decreased sensitivity to drug side effects over time as the brain adapts to the medication.
Which monoamines act as neurotransmitters in the central nervous system? (Select all that apply.) a. Acetylcholine b. Norepinephrine c. Serotonin d. Dopamine e. Epinephrine f. Histamine
B, C, D, E
Acetylcholine and histamines are not monoamines.
A patient has taken levodopa (Dopar) for Parkinson’s disease for 2 weeks but reports no improvement in the symptoms. Which response by the nurse is correct?
a.
“Another agent will be needed to manage your symptoms.”
b.
“Double the dose to see whether an effect occurs.”
c.
“It may take several months for a response to occur.”
d.
“The prescriber may need to change your drug regimen.”
C
A full therapeutic response with levodopa may take several months to develop. Until the true effect of the dose is seen, it is not necessary to change to another drug, increase the dose, or change the drug regimen.
A nurse provides teaching for a patient who is newly diagnosed with Parkinson’s disease. Which statement by the patient indicates understanding of the drug therapy for this disease?
a.
“A levodopa/carbidopa combination is used to improve motor function.”
b.
“There are several drugs available to treat dyskinesias.”
c.
“When ‘off’ times occur, I may need to increase my dose of levodopa.”
d.
“With adequate drug therapy, the disease progression may be slowed.”
A
Levodopa combined with carbidopa is the initial drug of choice to treat motor symptoms. Amantadine is the only drug recommended to treat dyskinesias. Entacapone and rasagiline are used to treat abrupt loss of effect, or “off” times. Drug therapy does not slow the progression of the disease.
A patient has been diagnosed with Parkinson’s disease (PD) and begins treatment with levodopa/carbidopa (Sinemet). After several months of therapy, the patient reports no change in symptoms. The nurse will expect the provider to: a. add a dopamine agonist. b. discuss the “on-off” phenomenon. c. increase the dose of Sinemet. d. re-evaluate the diagnosis.
D
Patients beginning therapy with levodopa/carbidopa should expect therapeutic effects to occur after several months of treatment. Levodopa is so effective that a diagnosis of PD should be questioned if the patient fails to respond in this time frame. Adding a dopamine agonist is not indicated. The “on-off” phenomenon occurs when therapeutic effects are present. Increasing the dose of levodopa/carbidopa is not indicated.
A patient with Parkinson’s disease is taking levodopa/carbidopa (Sinemet) and reports occasional periods of loss of drug effect lasting from minutes to several hours. The nurse questions the patient further and discovers that these episodes occur at different times related to the medication administration. The nurse will contact the provider to discuss:
a.
administering a catechol-O-methyltransferase (COMT) inhibitor, such as entacapone.
b.
adding the DA-releasing agent amantadine to the regimen.
c.
giving a direct-acting dopamine agonist.
d.
shortening the dosing interval of levodopa/carbidopa.
A
This patient is describing abrupt loss of effect, or the “off” phenomenon, which is treated with entacapone or another COMT inhibitor. Amantadine is used to treat dyskinesias. A direct-acting dopamine agonist is useful for gradual loss of effect, which occurs at the end of the dosing interval as the dose is wearing off. Shortening the dosing interval does not help with abrupt loss of effect.
A patient newly diagnosed with Parkinson’s disease has been taking levodopa/carbidopa (Sinemet) for several weeks and complains of nausea and vomiting. The nurse tells the patient to discuss what with the provider?
a.
Taking a lower dose on an empty stomach
b.
Taking an increased dose along with a high-protein snack
c.
Taking a lower dose with a low-protein snack
d.
Taking dopamine in addition to levodopa/carbidopa
C
Because levodopa activates the chemoreceptive trigger zone (CTZ) of the medulla, causing nausea and vomiting (N/V), the patient may need to take a lower dose temporarily until tolerance develops. A meal helps slow absorption to minimize this side effect. A high protein intake contributes to abrupt loss of effect, so meals should be low in protein. Taking a dose on an empty stomach increases absorption and also N/V. An increased dose with a high-protein snack increases N/V and also abrupt loss of effect. Dopamine increases N/V, because it activates the CTZ of the medulla.
A nurse is discussing motor symptoms with a patient with Parkinson’s disease who has been taking levodopa/carbidopa (Sinemet) and who is now having regular tics. Which statement by the patient indicates understanding of this symptom?
a.
“I may need to try a lower dose of Sinemet to reduce my tics.”
b.
“My provider may order clozapine to treat these tics.”
c.
“These tics are an indication that my dose of Sinemet is too low.”
d.
“This means I will have to have surgery to stop the symptoms.”
A
Levodopa can cause movement disorders. If they occur, a lower dose of levodopa may be required to alleviate them. Clozapine is an antipsychotic used to treat levodopa-induced psychoses. Movement disorders generally occur as the dose of levodopa increases. Surgery is a last option for treating movement disorders, after amantadine fails.
A patient who has begun taking levodopa/carbidopa (Sinemet) reports feeling lightheaded and dizzy, especially when standing up from a sitting position. What will the nurse recommend?
a.
An alpha-adrenergic antagonist medication
b.
Discussing amantadine with the prescriber
c.
Increasing the salt and water intake
d.
Taking a drug holiday
C
Postural hypotension is common early in treatment and can be reduced by increasing the intake of salt and water. An alpha-adrenergic agonist, not an antagonist, can help. Amantadine is used to treat levodopa-induced dyskinesias. Drug holidays are used when adverse effects increase with long-term use of levodopa; the drug holiday allows beneficial effects to be achieved with lower doses, which reduces the incidence of side effects.
A nursing student wants to know why a patient who has been taking levodopa (Dopar) for years will now receive levodopa/carbidopa (Sinemet). The nurse explains the reasons that levodopa as a single agent is no longer available. Which statement by the student indicates a need for further education?
a.
“Carbidopa increases the availability of levodopa in the central nervous system.”
b.
“Carbidopa reduces the incidence of nausea and vomiting.”
c.
“Combination products reduce peripheral cardiovascular side effects.”
d.
“Combination products cause fewer dyskinesias and decreased psychosis.”
D
Adding carbidopa to levodopa does not reduce the incidence of dyskinesias or psychosis. In fact, carbidopa can increase the intensity and the speed of onset of these effects. Carbidopa inhibits decarboxylation of levodopa in the intestine and peripheral tissues, leading to more levodopa in the CNS. Carbidopa cannot cross the blood-brain barrier, so it does not have this action in the CNS. Peripheral side effects are reduced, including nausea, vomiting, and cardiovascular effects.
A nurse is teaching a group of nurses about Parkinson’s medications. The nurse is correct to state that one side effect associated with pramipexole (Mirapex) that is less likely to occur with other dopamine agonists is: a. sleep attacks. b. dizziness. c. hallucinations. d. dyskinesias.
A
A few patients taking pramipexole have experienced sleep attacks, or an overwhelming and irresistible sleepiness that comes on without warning. Dizziness, hallucinations, and dyskinesias are listed as side effects of pramipexole and other dopamine agonists.
A nursing student wants to know how carbidopa can be effective for treating Parkinson’s disease if it prevents the conversion of levodopa to dopamine. The nurse explains that carbidopa: a. can be taken with high-protein meals. b. does not cross the blood-brain barrier. c. has dopamine-like effects of its own. d. reduces abrupt loss of effect.
B
Carbidopa inhibits decarboxylation of levodopa in the intestine and peripheral tissues, leading to more levodopa in the CNS. Carbidopa cannot cross the blood-brain barrier, so it does not have this action in the CNS. Carbidopa is not given with high-protein meals. Carbidopa does not have dopamine-like effects. Carbidopa does not affect abrupt loss of effect.
A 25-year-old patient has been newly diagnosed with Parkinson’s disease, and the prescriber is considering using pramipexole (Mirapex). Before beginning therapy with this drug, the nurse will ask the patient about:
a.
any history of alcohol abuse or compulsive behaviors.
b.
any previous history of hypertension.
c.
difficulty falling asleep or staying asleep.
d.
whether any family members have experienced psychoses.
A
Pramipexole has been associated with impulse control disorders, and this risk increases in patients with a history of alcohol abuse or compulsive behaviors. Pramipexole increases the risk of hypotension and sleep attacks, so a history of hypertension or insomnia would not be cautionary. Unlike with levodopa, the risk of psychoses is not increased.
A hospitalized patient with Parkinson’s disease who is receiving apomorphine to treat “off” episodes develops nausea and vomiting. The nurse will discuss the use of which medication with the patient’s provider? a. Levodopa (Dopar) b. Ondansetron (Zofran) c. Prochlorperazine (Compazine) d. Trimethobenzamide (Tigan)
D
Trimethobenzamide can be used as an antiemetic in patients treated with apomorphine. Serotonin receptor agonists (e.g., ondansetron) and dopamine receptor antagonists (e.g., prochlorperazine) cannot be used, because they increase the risk of serious postural hypotension. Levodopa only increases nausea and vomiting.
A patient with Parkinson’s disease is taking levodopa/carbidopa (Sinemet). The prescriber orders bromocriptine (Parlodel) to treat dyskinesias. The nurse notes that the patient is agitated, and the patient reports having frequent nightmares. The nurse will contact the provider to discuss: a. adding an antipsychotic medication. b. changing from bromocriptine to cabergoline (Dostinex). c. reducing the dose of bromocriptine. d. reducing the dose of levodopa/carbidopa.
C
Bromocriptine is used to treat levodopa-induced dyskinesias and has dose-dependent psychologic side effects. The nurse should suggest reducing the dose of this drug to minimize these side effects. Adding an antipsychotic medication is not indicated. Cabergoline is not approved for this use. Reducing the dose of levodopa/carbidopa is not indicated.
A nurse is caring for an older adult man who has Alzheimer’s disease (AD). The patient’s daughter wants to know if testing can be done to determine her risk for developing the disease. What will the nurse tell her?
a.
Family history and female gender are both known to increase the risk.
b.
Genetic testing can provide a definitive measure of the risk.
c.
Patients with the apolipoprotein E2 gene (ApoE2) are more likely to develop the disease.
d.
Some biologic markers can be measured, but none is known to increase the risk.
D
Although several genes, proteins, and neurologic changes are associated with the presence of Alzheimer’s disease, none has been shown to have a direct causative link. Advancing age and a positive family history are the only two known risk factors. Female gender is not a known risk; the increased incidence among females may be the result of women living longer than men. No definitive genetic tests are available. The presence of ApoE2 seems to be protective.
The spouse of a patient who acts confused and forgetful wants to know if there is a test to determine whether the patient has Alzheimer’s disease. Which response by the nurse is correct?
a.
“A diagnosis is made by administering medications and observing for potential improvement in symptoms.”
b.
“The diagnosis is based on a patient’s age, family history, serum apolipoproteins, and genetic testing.”
c.
“Magnetic resonance imaging to demonstrate brain atrophy is the definitive test to determine Alzheimer’s disease.”
d.
“Proposed diagnostic criteria include measures of cognitive function and the presence of one known biomarker.”
D
In 2010 an international group of AD experts proposed revising diagnostic criteria to add the presence of at least one AD biomarker to current measures of cognitive function after a patient has been observed to have episodic memory impairment. The diagnosis currently is made by observing memory impairment and then measuring cognitive function. Most medications used for AD do not demonstrate sustained or unequivocal improvement, so they would not be useful for diagnostic purposes. The patient’s age and family history are risk factors. The serum ApoE level and genetic testing are not used to diagnose AD. Magnetic resonance imaging (MRI) can measure one brain marker of AD; however, brain atrophy has several different causes and is not definitive
An older adult patient with Alzheimer’s disease is admitted to the hospital. The patient’s spouse reports that the patient is often confused and gets lost walking to the store, which is 3 blocks from their home. That evening, the nurse observes the patient pacing the hall and screaming. What will the nurse do?
a.
Notify the provider of this patient’s worsening symptoms.
b.
Prepare the patient’s spouse for impending death from Alzheimer’s disease.
c.
Request an increase in the medication dose to treat the exacerbation in symptoms.
d.
Tell the spouse that this is an expected progression of the disease.
D
This patient is showing signs of the natural progression of AD. Behavior problems such as these occur in 70% to 90% of patients with AD as the disease progresses. There is no need to notify the provider to report these symptoms, because they are expected. The time from onset of symptoms to death usually is 4 to 8 years, but it may be as long as 20 years; this progression does not represent the final stages. Medications are not effective for preventing disease progression, and their effects on memory and cognition are modest, so requesting an increase in the drug dose would not help in this situation.
An older adult patient has confusion, memory loss, and disorientation in familiar surroundings. The patient has been taking donepezil (Aricept) 10 mg once daily for 6 months. The patient’s symptoms have begun to worsen, and the patient’s spouse asks if the medication dose can be increased. What will the nurse tell the spouse?
a.
The dose can be increased, because the patient has been taking the drug for longer than 3 months.
b.
The dose can be increased to twice daily dosing instead of once daily dosing.
c.
The increase in symptoms is the result of hepatotoxicity from the medication’s side effects.
d.
The patient must take the drug for longer than 1 year before the dose can be increased.
A
Donepezil is given for mild, moderate, and severe AD, and dosing may be increased, although it must be titrated up slowly. For patients with moderate to severe AD who have taken 10 mg once daily for at least 3 months, the dose can be increased to 23 mg once daily. Donepezil is not given twice daily. Donepezil does not cause hepatotoxicity; hepatotoxicity occurs with tacrine, the first acetylcholinesterase (AChE) inhibitor, which now is rarely used. Dosing is increased after 3 months, not 1 year.
A patient will begin taking a cholinesterase inhibitor for early Alzheimer’s disease. The nurse is teaching the patient’s spouse about the medication. Which statement by the spouse indicates a need for further teaching?
a.
“Gastrointestinal symptoms are common with this medication.”
b.
“People taking this drug should not take antihistamines.”
c.
“This drug helps neurons that aren’t already damaged to function better.”
d.
“This drug significantly slows the progression of the disease.”
D
Cholinesterase inhibitors produce modest improvements in cognition, behavior, and function and may slightly delay disease progression; they do not have a major impact on delaying progression of the disease. Gastrointestinal symptoms are common side effects. Drugs that block cholinergic receptors, including antihistamines, can reduce therapeutic effects and should be avoided. Cholinesterase inhibitors do not affect neurons already damaged, but they do improve function in those not yet affected.